Exact Sciences (EXAS) Q4 Revenue Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mail
Get Alerts EXAS Hot Sheet
Price: $104.91 --0%
Financial Fact:
Research and development: 7.63M
Today's EPS Names:
SMXT, NRIX, VFS, More
Financial Fact:
Research and development: 7.63M
Today's EPS Names:
SMXT, NRIX, VFS, More
Join SI Premium – FREE
Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($2.79), may not compare to the analyst estimate of ($0.22). Revenue for the quarter came in at $466.3 million versus the consensus estimate of $446.22 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- Artisan Partners Asset Management (APAM) PT Lowered at TD Cowen After 'Another Attrition-Driven Miss'
- Truist Names Top Infrastructure Services Stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
